BME
In January 2018, Paradigm Biopharmaceuticals Ltd announced that it had been granted a European patent for the treatment of Bone Marrow Edema Lesions with Pentosan Polysulfate Sodium (PPS), and throughout 2018 has validated the patent in European member states. The European registration enhances Paradigm’s already strong patent position, adding to previously granted registrations in Australia, the United States, Japan, China, Canada, Taiwan, Singapore and other countries across the Asia-Pacific.
So this is Bullshit then
BMEIn January 2018, Paradigm Biopharmaceuticals Ltd announced...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.005(1.79%) |
Mkt cap ! $96.19M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 28.5¢ | 27.0¢ | $55.31K | 200.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1072 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 3289 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |